Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial

Launched by BIOCODEX · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Concurrent Medication:
• Allowed:
• • Antiviral medication for HIV infection.
• Patients must have:
• • Documented HIV infection.
• • Chronic diarrhea (for at least 1 month) that is either a manifestation or complication of documented HIV infection.
• • Had a stool culture (Salmonella, Shigella, Campylobacter, and Clostridium difficile) and stool analysis for ova and parasite (O/P X 3) within the past 2 months.
• • Failed antimicrobial treatment for diarrhea OR received no prior antimicrobials for stool pathogens because stool cultures were negative.
• • Patients who are on antiviral medications for HIV infection must have received such medication for at least 2 weeks and must remain on stable dose for weeks 1 and 2 of study.
• Prior Medication:
• Allowed:
• • Prior antiviral medication for HIV infection (if on such medication, must have received it for at least 2 weeks).
• • Standard antimicrobial therapy for a documented positive gastrointestinal pathogen.
• • Exclusion Criteria
• Concurrent Medication:
• Excluded:
• • Gastrointestinal medications that cause diarrhea (e.g., magnesium-containing antacids, lactulose).
• • Maintenance antifungal medication for life-threatening fungal infections (other than fluconazole \<= 100 mg/day).

Trial Officials